



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

BS

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/202,359	05/21/1999	DORIT ARAD	104315	2806
7590	02/01/2005		EXAMINER	
EUGENIA S.HANSEN SIDLEY & AUSTIN 717 NORTH HARWOOD SUITE 3400 DALLAS, TX 752016407			LUKTON, DAVID	
			ART UNIT	PAPER NUMBER
			1653	
			DATE MAILED: 02/01/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Response to Rule 312 Communication</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/202,359		
	Examiner David Lukton	Art Unit 1653	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1.  The amendment filed on 23 February 2004 under 37 CFR 1.312 has been considered, and has been:

- a)  entered.
- b)  entered as directed to matters of form not affecting the scope of the invention.
- c)  disapproved because the amendment was filed after the payment of the issue fee.  
Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.
- d)  disapproved. See explanation below.
- e)  entered in part. See explanation below.


*All requested changes will be entered, with the exception of the following two:*

1. *The amendment to page 28, line 7 which requests that the phrase "non specific inhibition of other" be deleted, and replaced with the phrase "specifically inhibit".*
2. *The amendment to the paragraph that begins on page 26, line 11.*

*The first of these (the amendment to page 28, line 7) will not be entered because it constitutes new matter; in the specification as filed, "non-specific inhibition" of enzymes was referred to, whereas the amendment directs that "specific inhibition" of enzymes should be referred to.*

*The second of these (amendment to the paragraph that begins on page 26, line 11) will not be entered because the paragraph at issue contains a peptide sequence, but does not provide a "SEQ ID NO:" within the text of the paragraph.*

D. Lukton 1/28/05



JON WEBER  
SUPERVISORY PATENT EXAMINER